Few fields can claim to embrace the evolving role of technology in patient care as diabetes management. Nowhere is this desire to improve patient care and quality of life more evident than at the International Conference on Advanced Diabetes Technologies and Treatments. As the 17th Congress approaches his early March, the excitement surrounding the Congress and its vast number of participants continues to grow year after year.
Among the conference attendees and enthusiasts were Dr. Diana Isaacs, endocrine clinical pharmacist, director of diabetes technical education and training, and co-director of endocrine diseases in pregnancy at the Cleveland Clinic; They include Natalie Bellini, DNP, program director at the Cleveland Clinic; Diabetes technology at the University Hospital Diabetes and Metabolic Care Center. Ahead of this year’s premier diabetes technology conference, Isaacs and Bellini Diabetes Dialogue: Technology, Treatments, and Real-World Perspectives.
In this episode, the hosts discuss the featured sessions, device news to look forward to, what makes ATTD a unique and valuable experience for diabetes care teams, and how the conference’s annual yearbook sessions will highlight the field’s exciting Provides insight into how developments are summarized.
Disclosures related to Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Disclosures related to Dr. Bellini include Abbott Diabetes Care, MannKind, Prevention Bio, and others.
